logo

Trovagene Inc. (TROV)



Trade TROV now with
  Date
  Headline
10/9/2017 8:03:42 AM FDA Grants Orphan Drug Designation To Trovagene's PLK1 Inhibitor, PCM-075, For Treatment Of AML
8/9/2017 4:30:45 PM Trovagene Q2 Loss/share $0.26 Vs. Loss $0.34 Year Ago
7/27/2017 8:10:32 AM Trovagene Says FDA Accepted Its IND Application For PCM-075, A Polo-like Kinase 1 Inhibitor
7/12/2017 8:04:17 AM Trovagene Announces Agreement With Novogene For NextCollect In China
7/6/2017 8:05:32 AM Trovagene Engages PRA Health Sciences To Conduct Phase 1b/2 Trial Of PCM-075
6/27/2017 8:05:06 AM Trovagene Announces Submission Of Investigational NDA To Initiate Phase 1b/2 Trial Of PCM-075 For Acute Myeloid Leukemia
6/22/2017 8:05:26 AM Trovagene Announces Agreement With Global Biopharma Company To Utilize Trovera CtDNA Tests And Services In Cancer Trials
6/12/2017 8:05:53 AM Trovagene Agrees With AstraZeneca To Utilize Trovera CtDNA Test And Services In Prospective Biomarker Study
3/15/2017 4:15:28 PM Trovagene Q4 Loss/share $0.34 Vs. Loss $0.26 Year Ago
10/4/2016 6:04:50 AM Pancreatic Cancer Action Network Selects Trovagene As The Liquid Biopsy Provider To Participate In Precision Promise
7/12/2016 8:35:29 AM Trovagene, USC Norris Comprehensive Collaborate To Standardize Use Of Trovera CtDNA Liquid Biopsy Tests In Patient Care